InsidersTradesSigma
Dr. Reddy's Laboratories Limited Stock: price and directors' dealings · India · SEBI (PIT + SAST)
Follow the Dr. Reddy's Laboratories Limited share price and the full directors' dealings record of the company, a listed issuer based in India. Shares trade on IN IN, under the oversight of SEBI (PIT + SAST). Operating in the Health Care sector, Dr. Reddy's Laboratories Limited has recorded 406 reports. Market capitalisation: €1,050.9bn. The latest transaction was filed on 27 March 2026 (Purchase). Among the most active insiders: Dr. Reddy's Employees ESOS Trust. The full history is openly available.
406
Insider Decl.
0
Thresholds
€33m
241 ops.
Buy Volume
€28m
164 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Dr. Reddy's Laboratories Limited Hold (neutral), based on 39 analysts. Average price target: ₹1,331.77.
15Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 9,089 of 25,535 companies
59.1
score / 100
Value47
Quality71
FCF yld1.6%
Earn yld3.8%
EV/EBITDA15.3x
ROE12%
Gross mgn53%
Net mgn13%
Debt/EBITDA1.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 27 March 2026
Declarations406 total
3,675 shares@ ₹1,301.89990.0000% mcap42.1% of flowADR/GDR/FCCBSEBI:45230f24a84db46cc8b14b0c281a1f563076d1ee
Ideal exit: 21 Dec 2026 (T+270)
4,275 shares@ ₹1,267.150214.0% of flowEquity SharesSEBI:822ca6b2345cf2621e60ff9466315e91affff923
Ideal exit: 5 Sept 2026 (T+270)
4,775 shares@ ₹1,316.40100.0% of flowADR/GDR/FCCBSEBI:12397999a46a73696eb8b2cb38851e7b5df97759
Ideal exit: 12 Jun 2026 (T+270)
10,495 shares@ ₹1,260.8011.8% of flowADR/GDR/FCCBSEBI:71816ffee125b52204b6af171b43c9529dd5ef46
Ideal exit: 26 May 2026 (T+270)
7,450 shares@ ₹1,292.1012.8% of flowADR/GDR/FCCBSEBI:86d33db5422baec141b37128c053b753ec5e9f42
7,450 shares@ ₹1,291.60100.0% of flowADR/GDR/FCCBSEBI:9a07849b7fe719b923089f65397e5e5162acfe70
8,440 shares@ ₹1,325.4511.2% of flowEquity SharesSEBI:ca7e09c9c591c0642ad41a1868cf98765813d196
Ideal exit: 20 Mar 2026 (T+270)
1,495 shares@ ₹1,325.450211.1% of flowEquity SharesSEBI:c774b42f99bc9c9c69c9dcdc47e081bdb5446006
Ideal exit: 20 Mar 2026 (T+270)
1,250 shares@ ₹1,361.4504100.0% of flowEquity SharesSEBI:cbffd07a0456fe2014a1947757b32d1f55eba36d
Ideal exit: 11 Mar 2026 (T+270)
2,050 shares@ ₹1,361.45372.6% of flowEquity SharesSEBI:e7334e232c6c933eee2cf3cd4dfa11e5da1224c6
Ideal exit: 11 Mar 2026 (T+270)
1,670 shares@ ₹1,361.45036.2% of flowEquity SharesSEBI:e9ac179127cc280090adf9a413cd47f5985d558b
Ideal exit: 11 Mar 2026 (T+270)
1,412 shares@ ₹6,553.009.1% of flowADR/GDR/FCCBSEBI:14339ac2b99aa3e6de215c668612c78ee42b8ce8
Ideal exit: 17 Jun 2025 (T+270)
1,594 shares@ ₹6,553.0063.6% of flowADR/GDR/FCCBSEBI:c792667a8e4f2aa03d7372d7e23b406ecdcaee9e
Ideal exit: 17 Jun 2025 (T+270)
1,700 shares@ ₹6,651.413516.2% of flowADR/GDR/FCCBSEBI:485a090766fc1d5ae19b33ab176e9078af181b69
150 shares@ ₹6,914.0047.6% of flowADR/GDR/FCCBSEBI:98fb5c592eeec2578963d0b26554f66fbdd3c543
Ideal exit: 26 May 2025 (T+270)
704 shares@ ₹6,914.0075.3% of flowADR/GDR/FCCBSEBI:b3e7e26b4f07a30cedee660c5ff6d5bbcdb58dc0
Ideal exit: 26 May 2025 (T+270)
145 shares@ ₹6,914.0033.1% of flowADR/GDR/FCCBSEBI:6fa92ed9233363a2096a34f71bebddd2f15c6897
Ideal exit: 26 May 2025 (T+270)
215 shares@ ₹6,914.0036.8% of flowADR/GDR/FCCBSEBI:b2a590e11b6e5f7bb729fc2e02c09600b6647802
Ideal exit: 26 May 2025 (T+270)
1,250 shares@ ₹6,914.724812.4% of flowADR/GDR/FCCBSEBI:67ec9ba677b0f9f575bd752fa42dd722f5bce9ea
Ideal exit: 26 May 2025 (T+270)
474 shares@ ₹6,914.0019.8% of flowADR/GDR/FCCBSEBI:dd58cd6759927e0612b21c8b7723db23a8dc4704
Ideal exit: 26 May 2025 (T+270)
594 shares@ ₹6,802.777811.8% of flowADR/GDR/FCCBSEBI:7ca38455e4ae5753d0bed2779c66d7c4221db444
Ideal exit: 26 May 2025 (T+270)
814 shares@ ₹6,914.006.1% of flowADR/GDR/FCCBSEBI:242380ba5867de3db5bc86037cc0fc97b993c2ec
Ideal exit: 26 May 2025 (T+270)
27,635 shares@ ₹16,134.78213.6% of flowADR/GDR/FCCBSEBI:5bd736ed73b8ad889442291f8e6dce5e6285d684
Ideal exit: 4 May 2025 (T+270)
65,500 shares@ ₹6,711.42613.6% of flowADR/GDR/FCCBSEBI:684be7024ba26d6180e0e5b111479e0c0404c6ba
625 shares@ ₹6,095.10085.7% of flowADR/GDR/FCCBSEBI:d2cb053c5c71d12be79b2aa234dd5992cd94263a
Ideal exit: 11 Mar 2025 (T+270)
25 of 406 declarations
About Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited is an Indian pharmaceutical company that develops, manufactures, and markets a wide range of generic medications, branded drugs, and biologics. It is listed on the Bombay Stock Exchange.